"Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma" - John Schieszer, MA
Over the past few years, approaches to treating multiple myeloma have changed significantly. In particular, pomalidomide, a third-generation immunomodulatory drug, has emerged as a potent potential component of combination therapies. “Triplet therapies have really emerged as the standard of care for most patients, with the next question being the role of quadruplet therapies,” said Joshua Richter, MD, assistant professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai. Dr. Richter added that there are many therapeutic combinations with or without pomalidomide that may improve outcomes in patients with MM. However, figuring out optimal combinations and sequencing may present an obstacle.
— Joshua Richter, MD, Assistant Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai